Previous 10 | Next 10 |
Thinly traded nano cap Protalix BioTherapeutics (NYSEMKT: PLX ) is up 18% premarket on modest volume in reaction to 12-month data on pegunigalsidase alfa (PRX-102) from the first 16 Fabry subjects in the open-label Phase 3 BRIDGE switchover study. More news on: Protali...
A preliminary analysis from the nonpartisan Congressional Budget Office (CBO) found that House Speaker Nancy Pelosi's (D-CA 12th District) bill to lower drug prices would save Medicare $345B between 2023 and 2029 by allowing the Secretary of Health and Human Services to negotiated lower pr...
In another transaction consistent with its stated strategy of sharpening its focus on areas that can deliver long-term growth while deleveraging after the Shire acquisition, Takeda Pharmaceutical Company (NYSE: TAK ) has agreed to divest certain assets. More news on: Takeda Pharmaceutica...
Transaction accelerates deleveraging Agreement simplifies portfolio in Takeda’s NEMEA region Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-c...
It can be hard for a non-scientist to judge the validity of a biotech's claims. Are this company's drugs going to be approved by the FDA? How valid is its research? These questions are almost impossible to answer. Even the scientists themselves can't be sure they're right until the clinical tria...
Prometheus Biosciences and Takeda Pharmaceutical (NYSE: TAK ) have entered a multi-target strategic collaboration to develop targeted therapies for inflammatory bowel disease. More news on: Takeda Pharmaceutical Company Limited, Healthcare stocks news, Read more ...
Results from a Phase 1 proof-of-concept study evaluating Takeda Pharmaceutical's (NYSE: TAK ) TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1 (NT1) showed a treatment effect. The data were presented at the World Sleep Congress in Vancouver. ...
− Early proof of concept study showed TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo − A second Phase 1 study in healthy sleep-deprived adults demonstrated that TAK-925 was well tolerated and increased wakefu...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio ® ) to the anti-tumor necrosis factor-alpha (anti-TNFα...
An open-label Phase 2 clinical trial evaluating Takeda Pharmaceutical Company's (NYSE: TAK ) maribavir (TAK-620) in patients with cytomegalovirus (CMV) infection after undergoing hematopoietic cell transplant or solid organ transplant showed a more significant treatment effect compared to ...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...